

EFFECT OF ORAL SODIUM BICARBONATE IN MAINTAINING ACID BASE BALANCE AND QOL IN CHRONIC KIDNEY DISEASE AND LONG-TERM ACIDOSIS

Comment [Dr Manish1]: Article was not written properly. Require huge and whole revision. Prepare it according to the STROBE guideline.

ABSTRACT :

Comment [Dr Manish2]: Make Abstract according to journal guideline

AIM: Aim of the study is to determine the effect of oral sodium bicarbonate in maintaining acid base balance and quality of life in chronic kidney disease and long-term acidosis patients.

Study design: A prospective observational study.

Study population: Approximately 174 people who came to nephrology department.

Study Duration : 6 months (December 2021- May 2022)

Comment [Dr Manish3]: Include these matters in methodology but without giving headings.

METHODOLOGY: : A prospective observational study on **EFFECT OF ORAL SODIUM BICARBONATE IN MAINTAINING ACID BASE BALANCE AND QUALITY OF LIFE IN CHRONIC KIDNEY DISEASE AND LONG TERM ACIDOSIS PATIENT'S** which was carried out in the Department of.

Comment [Dr Manish4]: Methodology written wrongly and doesn't highlight the matter of methods used for the research work.

Formatted: Font: Not Bold

RESULTS: Most of the patients are in between the age of 70-80 years, married, with good nutritional status, with minimum 5 months of CKD ,approximately 50% of the patients are suffering from HTN along with CKD followed by diabetes. Patients are using **OSB** for a minimum of 5 months with 500mg dose given thrice a day, along with Calcium channel blockers and pantoprazole. OSB is given as a oral tablet.

Comment [Dr Manish5]: This is not require in abstract.

Comment [Dr Manish6]: Results were missing. Matter mentioned here are not highlight the results. They should include in methods.

Comment [Dr Manish7]: What is OSB ? Don't use abbreviation in abstract.

CONCLUSION: Oral bicarbonate is widely used to correct acidosis in advanced CKD, this is not underpinned by trial evidence, and real uncertainty exists regarding the balance of benefit and risk for this intervention. That we concluded that most of the patients using OSB was analyzed from nephrology department in QOL, in maintaining acid-base balance was observed in CKD patients.

Comment [Dr Manish8]: Not mentioned properly. It is not according to the aim.

KEYWORDS: Chronic kidney disease, Metabolic disease, Oral sodium bicarbonate, Quality of life.

Comment [Dr Manish9]: Sentence doesn't make any sense.

1.INTRODUCTION:Chronic kidney disease (CKD) is the progressive, irreversible decreasing of renal function. Which is resulting from long standing disease, CKD sometimes derives from ARF that does not respond to treatment. [1,15] In a clinical study in patients suffering with CKD (creatinine 1.5-3.0mg/dl/1.73(2)), sodium bicarbonate 600mg orally 3 times a day were administered to preserve renal function. Serum bicarbonate was adjusted as needed to maintain serum bicarbonate levels of at least 23mmol per liter Decreased pH due to HCO₃ – reduction is known as metabolic acidosis.[3,24]

Bicarbonate deficit – blood concentration of bicarbonate decreases from 22mEq/L.Oral sodium bicarbonate is used in treating metabolic acidosis in patients suffering with CKD.[5]

2.MATERIALS AND METHODS/EXPERIMENTAL DETAILS/METHODOLOGY:

Sodium Bicarbonate In Maintaining Acid Base Balance And Quality Of Life In Chronic Kidney Disease And Long Term Acidosis Patient's which was carried out in the Department of nephrology.

Study design: A prospective observational study.

Place of study: A prospective observational study on Effect Of OralSodium Bicarbonate In Maintaining Acid Base Balance And Quality Of Life In Chronic Kidney Disease And Long Term Acidosis Patient's which was carried out in the Department of nephrology.

Study population: Approximately 174 people who came to nephrology department.

Study criteria / patient enrollment: Patients are enrolled in study based on inclusion and exclusion criteria.

Inclusion criteria: the patients who are diagnosed with CKD and receiving oral sodium bicarbonate as part of treatment

Exclusion criteria: the patients who are having other comorbidities, hypertension, diabetes, and other cardiovascular problems who are not given with oral sodium bicarbonate.

Study Materials:

A.Patient informed consent form

B.A specially designed patient data collection proforma.

Study Method: This study will be initiated after obtaining the permission from the institutional review board. the patients will be enrolled in study after taking informed consent from them, the enrolment of patient will be done on basis of inclusion and exclusion criteria.

The data for the present will be collected by graph pad prism, which is well-suited to identify all necessary baseline information, which includes

Comment [Dr Manish10]: Will be ??? what it means ?

Patient demographics like

Study procedure:

Age

Socio economic status

Educational status

High risk factors

Past and present history

Laboratory data

Radiographic data

Physiscian medication order form

NURSE'S medication administration record (drug chart) and any other verbal communication data

1. Analytical epidemiologic studies are most useful for testing a hypothesized association between human exposure and health effects. Analytic study design includes prospective studies.

A prospective observational study was conducted for six months of duration in the NEPHROLOGY DEPARTMENT.

Based on inclusion and exclusion criteria the CKD patients receiving oral sodium bicarbonate were recruited in the study.

The data was collected from graph pad prism and personal (patient representative /and patient). Interviews, by using a well – structured.

Patient data collection proforma and followed up.

All the necessary and relevant baseline information was collected on patient data collection proforma which includes:

Patient demographic details such as age, gender, personal history, habits, and employment status.

Past medication history.

Past medical history.

Present medication.

Risk factors (modifiable and non-modifiable).

The collected and documented data was analyzed based on following parameters.

1. PATIENT DISTRIBUTION BASED ON DEMOGRAPHIC DATA:

Patient distribution based on age

Patient distribution based on gender

Patient distribution based on personal history and social habits.

2. Patient distribution based on risk factors

3. Patient distribution based on drug regimen.

4. Patient distribution based on stage of CKD.

Statistical analysis:

The Percentage method was used to analyse the patient distribution based on various parameters.

T-test will be performed to calculate p-value for the purpose of comparison of results.

RESULTS AND DISCUSSION: Most of the patients are in between the age of 70-80 years, married, with good nutritional status, with minimum 5 months of CKD, approximately 50% of the patients are suffering from HTN along with CKD followed by diabetes. Patients are using OSB for a minimum of 5 months with 500mg dose given thrice a day, along with Calcium channel blockers and pantoprazole. OSB is given as an oral tablet. In our study we have gathered the data of the patients who are using oral sodium bicarbonate are considered based on inclusion and exclusion criteria. The main reason for admission in the nephrology ward and reasons for using oral sodium bicarbonate are evaluated and estimated in the CKD patients. The comorbid conditions of the patients and duration of treatment its effects are also analyzed. Mostly the information regarding oral sodium bicarbonate is analyzed and documented. The quality of life of the patient before and after oral sodium bicarbonate usage and treatment outcomes changes in lifestyle was also discussed. The following tables are used to obtain results.

Table:1 Showing age, marital status, nutritional status and education of patients.

Age	No. of patients	Percentage(%)
10-20	2	1.14
20-30	6	3.44
30-40	19	10.91
50-60	36	20.68
60-70	38	21.83
70-80	51	29.31

80-90	22	12.643
90-100	00	00
Marital status		
Married	166	95.4
Unmarried	8	4.5
Education		
Primary education	2	1.1
Secondary education	120	68.9
Higher education	4	2.2
Uneducated	48	27.5
Nutritional status		
Excellent	13	7.47
Good	97	55.7
Poor	64	36.7

Table:2 Showing duration of chronic kidney disease

Duration of CKD	No. of patients	Percentage(%)
12	32	18.39
5	74	42.52
1	13	7.47
3	34	19.54
6	3	1.72
8	18	10.34

Table:3 Showing reasons for patient admission

Reason for admission	No. of patients	Percentage(%)
CKD with HTN	86	49.42
DCMP WITH LV Dysfunction	22	12.6
DM with CKD	38	21.38
Urosepsis	12	6.8
Anemia	8	4.59
UTI	8	4.59

Table:4 Showing treatment outcomes

Treatment outcomes	No. of patients	Percentage(%)
--------------------	-----------------	---------------

Recovered	124	71.26
Not recovered	47	27.0
No change	00	00
Shifted to higher centres	00	00
Left against to medical advice	00	00
Economic burden	3	1.724

Table:5 Showing Duration of oral sodium bicarbonate

Sodium bicarbonate duration (months)	No . of patients	Percentage (%)
1	13	7.47
3	34	19.54
5	106	60.91
6	3	1.72
8	18	10.34




Figure 1 : Duration of oral sodium bicarbonate

Table:6 Showing routes of oral sodium bicarbonate

Sodium bicarbonate route	No. of patients	Percentage (%)
--------------------------	-----------------	----------------

Oral	174	100
Other routes	0	0

Table:7 Showing treatment for metabolic acidosis

Treatment for acid base balance	No. of patients	Percentage (%)
Sodax	116	66.66
Sobonix	1	0.57
Sobosis	57	32.75

Table:8 Showing doses of oral sodium bicarbonate

Dose of oral sodium bicarbonate	No. of patients	Percentage(%)
1 gm ,OD	35	20.11%
500mg , TID	139	79.88%

Table 9:Showing different class of drugs used in CKD

Class of drug	No. of patients	Percentage(%)
Calcium channel blockers	97	55.74%
Aminoglycosides antibiotics	53	30.45%
Cephalosporin antibiotics	72	41.37%
Nutritional supplements	159	91.37%
Antacids	162	93.1%
Ca supplements	45	25.8%
Alkalisising agent	174	100%

Table:10 Showing mostly used drugs with oral sodium bicarbonate.

Drug	No. of patients	Percentage(%)
Tab.Nicardia	97	55.74%
Tab.Lasix	72	41.37%
Tab.Azithromycin	53	30.45%
Tab.Cefglobe	72	41.37%
Tab.Pantoprazole	162	93.1%
Tab.Shelcal	45	25.8%
Tab.Meropenem	46	26.43%

Table:11 Showing quality of life of patients

Quality of life	No. of patients	Percentage(%)
Excellent	44	25.28
Good	69	39.65
Poor	61	35.05

CONCLUSION:

Oral bicarbonate is widely used to correct acidosis in advanced CKD, this is not underpinned by trial evidence, and real uncertainty exists regarding the balance of benefit and risk for this intervention. As most patients with CKD are old, and many are frail, it is critical that trials testing such interventions enroll typical patients and use outcome measures that are relevant to older people. Few older people with even advanced CKD will progress to end-stage renal disease; the risk of death from cardiovascular disease or infection often supervenes long before the need for renal replacement therapy. The range of outcomes selected for this study will allow an estimation of overall net benefit or harm across a range of disease outcomes including renal, and also maintaining acid base balance, as well as focusing on outcomes that are important to patients. So that we concluded that most of the patients using OSB was analyzed from nephrology department in QOL, in maintaining acid-base balance was observed in CKD patients .OSB supplements produce a dose dependent increase in serum bicarbonate was observed. Clinicians and clinical pharmacists have updated knowledge for treating the condition by using OSB. Future studies should determine improvement in functional outcomes in patients with CKD.

REFERENCES:

- 1.Comprehensive pharmacy review for NAPLEX, VIIIthedition 2013 By Leon Shargel,AlanH.Mutnick,PaulF.Souney,LarryN.Swanson ,chapter 48 page no.986-990.Published by Wolters Kluwer health.
- 2.Quality of life patient needs power point presentation by Dr.MagdaBayoumi, Lecturer,Nursingcollege,KingSaudUniversity.<https://slideplayer.com/slide/5866944/>.
- 3.[https://www.kidney-international.org/article/S0085-2538\(15\)54104-5/fulltext](https://www.kidney-international.org/article/S0085-2538(15)54104-5/fulltext)
- 4.[https://www.ackdjournal.org/article/S1548-5595\(07\)00098-5/fulltext](https://www.ackdjournal.org/article/S1548-5595(07)00098-5/fulltext)
5. Product Information: sodium bicarbonate IV injection, sodium bicarbonate IV injection.Hospira,Inc,LakeForest,IL,2006.
6. Product Information: sodium bicarbonate oral tablets, sodium bicarbonate oral tablets.RugbyLaboratories,Inc,Duluth,GA,2008.
7. Product Information: BRIOSCHI effervescent antacid, sodium bicarbonate

effervescent..antacid.Brioschi,Inc,FairLawn,NJ,2005.

8.VandenHoek TL , Morrison LJ , Shuster M , et al: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care science. Part 12: cardiac arrest in special situations. *Circulation*2010;122(18Suppl3):S829-S861.

9. de Brito-Ashurst I, Varaganam M, Raftery MJ, et al: Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am SocNephrol*2009;20(9):2075-2084.[PubMedAbstract:http://www.ncbi.nlm.nih.gov/...](http://www.ncbi.nlm.nih.gov/...)

10.Kleinman ME, Chameides L, Schexnayder SM, et al: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 14: pediatric advanced life support. *Circulation* 2010; 122(18Suppl.3):S876-S908.

11. Kleinman ME , Chameides L , Schexnayder SM , et al: Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Pediatrics* 2010; 126(5):e1361-e1399.

12. Wear J, McPherson TB, &Kolling WM: Stability of sodium bicarbonate solutions in polyolefin bags. *Am J Health Syst Pharm* 2010; 67(12):1026-1029.[PubMedAbstract:http://www.ncbi.nlm.nih.gov/...](http://www.ncbi.nlm.nih.gov/...)

13. Mylan Suma Bhuvana, Murthysetty Likitha, Thirugabathina Swathi, A.C Nikila Teja, Dr. Kudipudi Harinadha Baba, Dr. Kanamala Arun Chand Roby (2021). Evaluation of Safety and Efficacy of Antibiotics in Respiratory Tract Infection Patients in a Tertiary Care Teaching Hospital: Prospective Observational Study. *Int Res J Clin Stud Pharm Trends*, 1(2);1-6.[PubMedAbstract:http://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

14. Kirkland WD, Jones RW, Ellis JR, et al: Compatibility studies of parenteral admixtures.*AmJHospPharm*1961;18:694-699.

15. Brar SS, Shen AY, Jorgensen MB, et al: Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA* 2008; 300(9):1038-1046.[PubMedAbstract:http://www.ncbi.nlm.nih.gov/...](http://www.ncbi.nlm.nih.gov/...)

16. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA* 2004;291(19):2328-2334.[PubMedAbstract:http://www.ncbi.nlm.nih.gov/...](http://www.ncbi.nlm.nih.gov/...)

17. Product Information: sodium bicarbonate intravenous injection solution, sodium bicarbonate intravenous injection solution. Fresenius Kabi USA, LLC (perDailyMed),LakeZurich,IL,2013.

18. Roby KAC, Bhargavi SL, Sri GD, Madhuri A, Kamakshi S, Bhagyaraj K, et al. Effect of a novel coronavirus in human and its clinical diagnosis and implications by students of community pharmacy. *Int J Basic Clin Pharmacol* 2020;9:1140-6.
18. Product Information: Sodium bicarbonate injection, sodium bicarbonate. LyphoMed,1987.
19. Anon: Breastfeeding and Maternal Medication. World Health Organization, Geneva, Switzerland, 2002.
20. Hamm, LL; Nakhoul, N; Hering-Smith, KS (7 December 2015). "[Acid-Base Homeostasis](#)". *Clinical Journal of the American Society of Nephrology*. **10** (12): 2232–42. doi:10.2215/CJN.07400715. PMC 4670772. PMID 26597304.
21. J., Tortora, Gerard (2012). *Principles of anatomy & physiology*. Derrickson, Bryan. (13th ed.). Hoboken, NJ: Wiley. pp. 42–43. ISBN 9780470646083. OCLC 698163931.
22. Stryer, Lubert (1995). *Biochemistry (Fourth ed.)*. New York: W.H. Freeman and Company. pp. 347, 348. ISBN 0-7167-2009-4.
23. Adrogué, H. E.; Adrogué, H. J. (April 2001). "Acid-base physiology". *Respiratory Care*. **46** (4): 328–341. ISSN 0020-1324. PMID 11345941.
24. Garrett, Reginald H.; Grisham, Charles M (2010). *biochemistry*. Cengage Learning. p. 43. ISBN 978-0-495-10935-8.
25. Diem, K.; Lentner, C. (1970). "Blood – Inorganic substances". in: *Scientific Tables (Seventh ed.)*. Basle, Switzerland: CIBA-GEIGY Ltd. p. 527.
26. Caroline, Nancy (2013). *Nancy Caroline's Emergency care in the streets (7th ed.)*. Buffer systems: Jones & Bartlett Learning. pp. 347–349. ISBN 978-1449645861.
27. Hamm, L. Lee; Nakhoul, Nazih; Hering-Smith, Kathleen S. (2015-12-07) *acid base homeostasis*. *Clinical Journal of the American Society of Nephrology*. **10** (12): 2232–2242. doi:10.2215/CJN.07400715. ISSN 1555-905X. PMC 4670772. PMID 26597304.
28. Levitzky, Michael G. (2013). *Pulmonary physiology (Eighth ed.)*. New York: McGraw-Hill Medical. p. Chapter 9. Control of Breathing. ISBN 978-0-07-179313-1.
29. Rose, Burton; Helmut Rennke (1994) *renal pathophysiology*. Baltimore: Williams & Wilkins. ISBN 0-683-07354-0.
30. Brandis, Kerry. Acid-base physiology Respiratory acidosis: definition. http://www.anaesthesiamcq.com/AcidBaseBook/ab4_1.php
31. Maurizio Bosola., stefaniagiungi., luigitazza., et.al., "Long Term Oral Sodium Bicarbonate Supplementation Does Not Improve Serum Albumin Levels In Hemodialysis Patients" Published online: April 02,2007 PMID: 17409769 DOI:

10.1159/000101484. Published in: Clinical practice.

32. Miles D Witham., Margaret., aimunahmed., et.al, “Clinical And Cost Effective Of Oral Sodium Bicarbonate Therapy For Older Patients With CKD And Low Grade Acidosis A Programmatic ,Double Blind ,Placebo-Controlled Trial” . Published Online: April 09,2020. PMID :32268897. DOI :PMC7144058. Published in : Research article

33. Vandana Menon., Hocinetighiouart., Nubia Smith Vaughn., et.al., “Bicarbonate And Long Term Outcomes In Chronic Kidney Disease” Published on : June 04,2010. PMID :20605301 DOI: 10.10530/j.akjd .2010.03. 023. Published in: American society of nephrology

34. Fang Cheng., Seinlinli., Jinglinwang. et.al., “ The effect of oral sodium bicarbonate on renal functions and CVS risk in patients with CKD -A systematic review and meta-analysis”. Published on : 7 December ,2021. PMID :34908841 DOI: 10.2147/TCRM.S344592. Published in: Threptic and clinical risk management.

35. Kalani Raphael., Tamara Isakova., et.al., “A Randomized Trial Comparing The Safety, Adherence And Pharmacodynamic Profiles Of 2 Doses Of Sodium Bicarbonate In CKD The Base Pilot Trial”. Published online :17 December,2019 PMID :31848294 DOI :10.1681/ASN.2019030287 .Published in :American society of nephrology

36. Michal Melamed., Edward Horwitz., Thomas Hostetter “Effects Of Sodium Bicarbonate In CKD Stages 3 And 4: A Randomized, Placebo – Controlled, Multicenter Clinical Trial”. Published online: November 5,2019 PMID :31699517 DOI: 10.1053/j.ajkd.2019.07.018. Published in: American journal of kidney disease

37. Suhan Alva., Deviate., Sharma parkas “ A Study On Effect Of Bicarbonate Supplementation On Progression Of Chronic Kidney Disease” Published Online :Feb 11,2020 PMID: 32269432 DOI: 10.4103/ijn.IJN _93_19. Published in : Indian journal of nephrology

38. Christof Aigner., Daniel Ceja., Christopher Sliber., et.al., “Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity In Patients With Chronic Kidney Disease And Chronic Metabolic Acidosis” Published online: October 16, 2018 PMID: 31067546 DOI: 10.1159/0004. Published in: clinical trials.

39. Biagio R. Di Di Orio., Antonio Belasis., et.al., “Treatment Of Metabolic Acidosis With Sodium Bicarbonate Delays Progression Of Chronic Kidney Disease: The UBI Study”. Published Online :October 9,2019, PMID :31598912, DOI :10.1007/s406020-019-00656-5. Published in :American society of nephrology

40. Paweena Susantitaphong., Kamal Sewaralthahab., Nicholas E. Madias “Short- And Long-

Term Effects Of Alkali Therapy In Chronic Kidney Disease: A Systematic Review”.
Published Online : May 29,2012 PMID :22653322 DOI :10.1159/000339329 .Published in
:American society of nephrology

41.LineDeBrito., Mira.,Muhammad., M.Yaqoob “Bicarbonatesupplementation Slows
Progression Of CKD And Improves Nutritional Status.” .Published Online: May 18,2009
PMID :19608703 DOI :10.1681/ASN.2008111205. Published in: American society of
nephrology

42.Dennis Y Wu.,et.al., “Association Between Serum Bicarbonate And Death In
Hemodialysis Patients: Is It Better To Be Acidotic Or Alkalotic?” Published Online: October
20,2005 DOI :10.2215/CJN.00010505. Published in: American society of nephrology

43.Baris Afar.,Reinsurer “Association Between Serum Bicarbonate And Ph. With
Depression ,Cognition And Sleep Quality In Hemodialysis Patients”
PublishedOnline:April20,2015,PMID:25894326,DOI:10.3109/0886022X.2015.1038476.Publ
ished in: Clinical study.

44.AndreasBodices., Iliana Kiriakou., SofiaSpaia., et.al., “Aiming For The Optimal
Bicarbonate Prescription For Maintenance Hemodialysis Therapy In
ESRD”PublishedOnline:Feb14,2019PMID:30762289DOI:10.1111/hdi.12710.Published in :
American society of nephrology

45.Philippe Choureau.,ClaireRouthier.,Christian Coombe “Con: Higher serum bicarbonate in
dialysis patient is protective”. Published Online: July 13,2016 PMID: 27411724 DOI:
10.1093/net/gfw255.Published in: Nephrology dialysis transplantation.

46.Cheuk-Chun Szeto.,et.al., “Oral Sodium Bicarbonate For The Treatment Of Metabolic
Acidosis In Peritoneal Dialysis Patient: A Randomized Placebo Control Trial”. Published
Online: July 21,2003 PMID: 12874466 DOI:10.1097/01.asn.0000080316.37254.7a Published
in: American society of nephrology.

47.Ezio Merville., Paola Gaga., CorradoCamerini., et.al., “Effect Of Oral Sodium Bicarbonate
Supplementation On Interdialytic Weight Gain, Plasma Sodium Concentrations And
Predialysis Blood Pressure In Hemodialysis Patients”.
.PublishedOnline:August25,2005PMID:16088106DOI:10.1159/000087195.Published in:
Clinical trial.

48.MartinaGaga., AlexanderRepitz., et.al., “Effect Of Oral Sodium Bicarbonate Treatment
On 24-Hour Ambulatory Blood Pressure Measurements In Patients With Chronic Kidney
Disease And Metabolic Acidosis”. Published Online: September06,2021DOI:

10.3389/fmed.2021.711034.Published in: Clinical research.

49. Daniel Cejka., Max Plischke., Alice Schmidt., et.al., "Effect Of Oral Sodium Bicarbonate Supplementation On Progression Of CKD In Patients With Chronic Metabolic Acidosis : Study Protocol For A Randomized Controlled Trial (So Bic-Study)". Published Online : July 04, 2013 PMID : 23826760 DOI : 10.1186/1745-6215-14-196 .Published in : Clinical trials.

50. Nimrit Goraya et.al., "Fruits And Vegetable Treatment Of Chronic Kidney Disease – Related Metabolic Acidosis Reduces Cardiovascular Risk Better Than Sodium Bicarbonate". Published Online: April 17, 2019 PMID: 30995657 DOI: 10.1159/00050004 2. Published in: American journal of nephrology.

ABBREVIATIONS:

SL.NO	ACRONYMS & ABBREVIATIONS	TERMINOLOGY
1	OSB	Oral Sodium Bicarbonate
2	QOL	Quality of life
3	CKD	Chronic Kidney Disease
4	GFR	Glomerular Filtration Rate
5	ARF	Acute Renal Failure
6	CHF	Congestive Heart Failure
7	GIF	Gastro Intestinal Tract
8	BUN	Blood Urea Nitrogen
9	ACE	Angiotensin Converting Enzyme
10	PT	Prothrombin Time
11	FDA	Food and Drug Administration
12	ESRD	End Stage Renal Disease
13	WHO	World Health organization

14	VA	Alveolar Ventilation
15	COPD	Chronic Obstructive Pulmonary Disease
16	ABG	Arterial Blood Gas
17	CO	Carbon monoxide
18	OHS	Obesity Hypoventilation Syndrome

